Teva’s Emrusolmin Receives FDA Fast Track Designation for Multiple System Atrophy Treatment
Teva Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational therapy emrusolmin (TEV-56286) for the…
Read More...
Read More...
